Catharanthalog

Catharanthalog
Clinical data
Other namesCAG
Drug classNon-hallucinogenic serotonin 5-HT2A receptor partial agonist
ATC code
  • None
Identifiers
  • methyl 3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indole-5-carboxylate
CAS Number
PubChem CID
Chemical and physical data
FormulaC15H18N2O2
Molar mass258.321 g·mol−1
3D model (JSmol)
  • CN1CCC2=C(C(C1)C(=O)OC)NC3=CC=CC=C23
  • InChI=1S/C15H18N2O2/c1-17-8-7-11-10-5-3-4-6-13(10)16-14(11)12(9-17)15(18)19-2/h3-6,12,16H,7-9H2,1-2H3
  • Key:BYQISFIBSIGMLV-UHFFFAOYSA-N

Catharanthalog (CAG) is a non-hallucinogenic serotonin receptor modulator of the ibogalog group related to the iboga alkaloid catharanthine but with a simplified chemical structure. It is known to act as a serotonin 5-HT2A receptor partial agonist. The drug produces analgesic-like effects in a neuropathic pain model in rodents that can be reduced by the serotonin 5-HT2A receptor antagonist ketanserin. Catharanthalog is said to have relatively low blood–brain barrier permeability owing to relatively low lipophilicity. It does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. The drug was first described in the scientific literature by 2025.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.